Last Week Seattle Genetics, Inc. (NASDAQ:SGEN) Ratings

May 17, 2018 - By Tamara Reed

Seattle Genetics, Inc. (NASDAQ:SGEN) Corporate Logo
Big Money Sentiment increased to 1.23 in 2017 Q4. It has change of 0.45, from 2017Q3’s 0.78. The ratio increased due to Seattle Genetics, Inc. positioning: 24 sold and 67 reduced. 44 funds bought stakes and 68 increased stakes. Investors holded 140.23 million in 2017Q3 but now own 141.83 million shares or 1.14% more.
Cap International reported 5.22M shs stake. 50,066 were reported by Citigroup. Landscape Capital Mgmt Ltd Company invested in 16,964 shs or 0.08% of the stock. 330 were reported by Pathstone Family Office Limited. British Columbia Management stated it has 0.01% of its capital in Seattle Genetics, Inc. (NASDAQ:SGEN). Renaissance Technology Ltd holds 0% or 43,113 shs. Amalgamated Bank reported 0.03% of its capital in Seattle Genetics, Inc. (NASDAQ:SGEN). Regions, a Alabama-based fund reported 1,400 shs. State Of Wisconsin Board stated it has 15,709 shs or 0% of all its holdings. Qs Investors Ltd Liability Corporation holds 0% or 3,511 shs in its capital. Jgp Gestao De Recursos Ltda reported 0.54% in Seattle Genetics, Inc. (NASDAQ:SGEN). Sei Investments Communications invested in 13,379 shs or 0% of the stock. Susquehanna Group Llp holds 0% in Seattle Genetics, Inc. (NASDAQ:SGEN) or 163,419 shs. Hsbc Holding Plc holds 0% of its capital in Seattle Genetics, Inc. (NASDAQ:SGEN) for 11,751 shs. 4,800 were reported by Stone Ridge Asset Mgmt Ltd Liability Co.

Seattle Genetics, Inc. had 10 selling transactions and 3 buys since December 11, 2017. This’s net activity of $268.25 million. On Monday, April 30 the insider BAKER BROS. ADVISORS LP bought $51.26 million. $552,452 worth of stock was sold by DRACHMAN JONATHAN G on Monday, March 5. On Thursday, March 15 Shares for $290,604 were sold by HIMES VAUGHN B. Cline Darren S had sold 4,000 shs worth $215,238.

Seattle Genetics, Inc. (NASDAQ:SGEN) Ratings Coverage

In total 8 analysts cover Seattle Genetics (NASDAQ:SGEN). “Buy” rating has 6, “Sell” are 0, while 2 are “Hold”. (NASDAQ:SGEN) has 75% bullish analysts. 11 are the (NASDAQ:SGEN)’s ratings reports on May 17, 2018 according to StockzIntelligence Inc. On Tuesday, March 20 RBC Capital Markets maintained Seattle Genetics, Inc. (NASDAQ:SGEN) with “Buy” rating. On Wednesday, February 7 the company was maintained by H.C. Wainwright. In Wednesday, January 31 report RBC Capital Markets maintained the stock with “Buy” rating. On Wednesday, February 7 the company was maintained by Needham. On Wednesday, February 14 the company was upgraded by JP Morgan. On Wednesday, February 14 J.P. Morgan upgraded Seattle Genetics, Inc. (NASDAQ:SGEN) rating. J.P. Morgan has “Buy” rating and $66.0 target. On Wednesday, March 21 the firm earned “Overweight” rating by Morgan Stanley. The company rating was maintained by H.C. Wainwright on Thursday, February 1. On Wednesday, February 7 the rating was maintained by Bank of America with “Neutral”. On Wednesday, February 7 SunTrust maintained Seattle Genetics, Inc. (NASDAQ:SGEN) rating. SunTrust has “Hold” rating and $60.0 target. Listed here are Seattle Genetics, Inc. (NASDAQ:SGEN) PTs and latest ratings.

27/04/2018 Broker: H.C. Wainwright Rating: Buy New Target: $77.0000 Maintain
21/03/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $69 New Target: $67 Maintain
20/03/2018 Broker: RBC Capital Markets Rating: Buy New Target: $73.0 Maintain
14/02/2018 Broker: J.P. Morgan Rating: Buy New Target: $66.0 Upgrade
14/02/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Overweight Old Target: $60 Upgrade
07/02/2018 Broker: Needham Rating: Buy New Target: $74.0 Maintain
07/02/2018 Broker: Bank of America Old Rating: Neutral New Rating: Neutral Old Target: $70 New Target: $68 Maintain
07/02/2018 Broker: H.C. Wainwright Rating: Buy New Target: $77.0 Maintain
07/02/2018 Broker: SunTrust Rating: Hold New Target: $60.0 Maintain
01/02/2018 Broker: H.C. Wainwright Rating: Buy New Target: $75.0 Maintain

SGEN touched $57.33 during the last trading session after $1.17 change.Seattle Genetics, Inc. has volume of 910,426 shares. Since May 17, 2017 SGEN has declined 20.48% and is downtrending. SGEN underperformed by 32.03% the S&P500.

Seattle Genetics, Inc., a biotechnology company, develops and commercializes targeted therapies to treat cancer worldwide.The firm is valued at $9.07 billion. It markets ADCETRIS, an antibody-drug conjugate for relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma.Last it reported negative earnings. The firm also develops SGN-CD33A that is in Phase III clinical trial to evaluate SGN-CD33A in combination with hypomethylating agents in previously untreated older patients, as well as in Phase 1/2 clinical trial for patients with relapsed or refractory acute myeloid leukemia ; ASG-22ME, which is in Phase I clinical trial for Nectin-4-positive solid tumors, including bladder cancer; SGN-LIV1A that is in Phase 1 clinical trial for patients with LIV-1-positive metastatic breast cancer; and SGN-CD19A, which is in Phase II clinical trial for patients with relapsed DLBCL, as well as in Phase II trial for patients with newly diagnosed DLBCL.

For more Seattle Genetics, Inc. (NASDAQ:SGEN) news announced recently go to: Businesswire.com, Seekingalpha.com, Businesswire.com, Streetinsider.com or Nasdaq.com. The titles are as follows: “Seattle Genetics Announces Data Presentations at 2018 ASCO Annual Meeting” announced on May 17, 2018, “Seattle Genetics (SGEN) Q1 2018 Results – Earnings Call Transcript” on April 27, 2018, “Seattle Genetics Appoints Roger D. Dansey, MD, Chief Medical Officer” with a publish date: May 17, 2018, “Seattle Genetics (SGEN) Announces Data Presentations at ASCO” and the last “Factors of Influence in 2018, Key Indicators and Opportunity within Patterson Companies, Zayo Group, Six Flags …” with publication date: May 09, 2018.

Seattle Genetics, Inc. (NASDAQ:SGEN) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.